• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].

作者信息

Ou Sai-Hong Ignatius, Cui Jean, Schrock Alexa B, Goldberg Michael E, Zhu Viola W, Albacker Lee, Stephens Philip J, Miller Vincent A, Ali Siraj M

机构信息

Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA, USA.

TP Therapeutics Inc, San Diego, CA, USA.

出版信息

Lung Cancer. 2019 Dec;138:141. doi: 10.1016/j.lungcan.2019.08.013. Epub 2019 Aug 22.

DOI:10.1016/j.lungcan.2019.08.013
PMID:31447233
Abstract
摘要

相似文献

1
Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].《一例接受奥希替尼治疗后进展的EGFR（L858R/T790M）非小细胞肺癌患者中出现新的、占主导地位的获得性EGFR溶剂前沿突变Gly796（G796S/R）以及C797S/G和L792F/H突变》的勘误[《肺癌》，第108卷（2017年6月），第228 - 231页]
Lung Cancer. 2019 Dec;138:141. doi: 10.1016/j.lungcan.2019.08.013. Epub 2019 Aug 22.
2
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.在一名接受奥希替尼治疗后病情进展的表皮生长因子受体（EGFR）（L858R/T790M）非小细胞肺癌（NSCLC）患者中，出现了新的、占主导地位的获得性EGFR溶剂前沿突变，位于甘氨酸796（G796S/R），同时伴有C797S/R和亮氨酸792（L792F/H）突变。
Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12.
3
Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.病例报告：奥希替尼进展后，一名携带EGFR L858R-T790M-cis-G796S和L718Q耐药突变的非小细胞肺癌患者对布加替尼、西妥昔单抗联合埃克替尼的联合治疗产生持久反应。
Front Oncol. 2022 Apr 21;12:875313. doi: 10.3389/fonc.2022.875313. eCollection 2022.
4
Acquired rare recurrent mutations as mechanisms of resistance to Osimertinib in lung cancer and structural modelling.获得性罕见复发性突变作为肺癌对奥希替尼耐药的机制及结构建模
Am J Cancer Res. 2020 Nov 1;10(11):4005-4015. eCollection 2020.
5
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.EGFR T790M 和 C797S 突变作为达克替尼获得性耐药的机制。
J Thorac Oncol. 2018 May;13(5):727-731. doi: 10.1016/j.jtho.2018.01.009. Epub 2018 Feb 2.
6
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.肺腺癌伴 EGFR T790M 和 in trans C797S 对第一代和第三代 EGFR TKI 联合治疗有反应，并在耐药时改变等位基因构型。
J Thorac Oncol. 2017 Nov;12(11):1723-1727. doi: 10.1016/j.jtho.2017.06.017. Epub 2017 Jun 27.
7
Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry.针对非小细胞肺癌中的 EGFR 和 EGFR 耐药突变：药物化学的最新进展。
Med Res Rev. 2018 Sep;38(5):1550-1581. doi: 10.1002/med.21488. Epub 2018 Jan 26.
8
Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.EGFR T790M/C797S/V948R 与 EAI045 复合物的晶体结构
Biochem Biophys Res Commun. 2018 Jul 20;502(3):332-337. doi: 10.1016/j.bbrc.2018.05.154.
9
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.基于标签的下一代测序：一种可行且可靠的方法，可用于检测非小细胞肺癌患者循环肿瘤 DNA 中的 EGFR T790M 突变。
Mol Med. 2019 Apr 27;25(1):15. doi: 10.1186/s10020-019-0082-5.
10
Structural insights into drug development strategy targeting EGFR T790M/C797S.针对表皮生长因子受体（EGFR）T790M/C797S的药物开发策略的结构见解
Oncotarget. 2018 Jan 10;9(17):13652-13665. doi: 10.18632/oncotarget.24113. eCollection 2018 Mar 2.

引用本文的文献

1
Genomics Analysis and Nomogram Risk Prediction of Occult Lymph Node Metastasis in Non-Predominant Micropapillary Component of Lung Adenocarcinoma Measuring ≤ 3 cm.≤3 cm肺腺癌非优势微乳头成分中隐匿性淋巴结转移的基因组分析及列线图风险预测
Front Oncol. 2022 Jul 13;12:945997. doi: 10.3389/fonc.2022.945997. eCollection 2022.
2
[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].[奥希替尼在非小细胞肺癌靶向治疗中的获得性耐药机制]
Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):274-281. doi: 10.3779/j.issn.1009-3419.2020.103.02.
3
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
癌细胞中对小分子抑制剂的继发性耐药突变
Cancers (Basel). 2020 Apr 9;12(4):927. doi: 10.3390/cancers12040927.